Moreover, as observed with AML, MDS patients with R882 mutations are found to have a significantly worse overall prognosis and a more rapid progression to leukemia than patients with non-R882 DNMT3A mutations. The gene discussed is DNMT3A; the disease is myelodysplastic syndrome.